Should socioeconomic factors be considered as traditional risk factors for cardiovascular disease, as confounders, or as risk modifiers?

Dialogues in Cardiovascular Medicine

Volumn 13, Issue 2, 2008, Pages 103-126

  De Vogli, Roberto ^a   Marmot, Michael ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Cardiovascular disease; Coronary heart disease; Social gradient; Socioeconomic condition; Socioeconomic factor

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IVABRADINE; LOW DENSITY LIPOPROTEIN; METOPROLOL; PLACEBO; SEX HORMONE; VERAPAMIL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE HEART INFARCTION; ALCOHOL CONSUMPTION; ANGINA PECTORIS; AUTONOMIC NERVOUS SYSTEM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CIGARETTE SMOKING; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DYSLIPIDEMIA; EARLY MENOPAUSE; EPIDEMIC; EPIDEMIOLOGICAL DATA; EXERCISE; FOOD INTAKE; HEALTH BEHAVIOR; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART RATE; HORMONE SUBSTITUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MALARIA; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; MORTALITY; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PREGNANCY DIABETES MELLITUS; REVIEW; RISK MANAGEMENT; RISK REDUCTION; SEX DIFFERENCE; SITTING; SOCIAL STATUS; SOCIAL STRESS; SOCIOECONOMICS; STABLE ANGINA PECTORIS; TACHYCARDIA; TUBERCULOSIS;

EID: 77951609758     PISSN: 12729949     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. World Health Organization. The World Health Report 2002. Reducing Risks, Promoting Healthy Life. World Health Organization: Geneva, Switzerland; 2002.
2. Yusuf S, Hawken S, Ounpuu S, et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case control study. Lancet. 2004;364:937-952. (Pubitemid 39208455)
3. Stramba-Badiale M, Fox KM, Priori SG, et al. The European Society of Cardiology Policy conference on cardiovascular diseases in women. Eur Heart J. 2006;27:994-1005.
4. Mosca L, Appel LJ, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation. 2004;109:672-693. (Pubitemid 38198877)
5. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837.
6. Ridker P, Buring EJ, Rifai N, Cooks NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women. JAMA. 2007;297:611-619.
7. Department of Health (2000) National Service Framework for Coronary Heart Disease. London, UK; 2000.
8. Woods D, Wray R, Poulter N, et al. JBS 2: Joint British Societies guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91(suppl V)V1-V52. (Pubitemid 43021884)
9. Al-Khalili F, Svane B, Wamala SP, Orth-Gomér K, Rydén L, Schenck-Gustafsson K. Clinical importance of risk factors and exercise testing for prediction of significant coronary artery stenosis in women recovering from unstable coronary artery disease: the Stockholm Female Coronary Risk Study. Am Heart J. 2000;139:971-978. (Pubitemid 30390324)
10. Jacobs DR, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow up study of the Lipid Research Clinics Prevalence study. Am J Epidemiol. 1990;131:132.
11. Legato MJ. Dyslipidemia, gender, and the role of high density lipoprotein cholesterol: implications for therapy. Am J Cardiol. 2000;86:15L-18L.
12. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection study of cholesterol lowering with Simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7.
13. Lewis SJ, Sacks FM, Mitchell JS, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol. 1998;32:140-146.
14. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
15. van der Giezen AM, Schopman-Geurts van Kessel JG, Schouten EG, Slotboom BJ, Kok FJ, Collette HJ. Systolic blood pressure and cardiovascular mortality among 13,740 Dutch women. Prev Med. 1990;19:456-465.
16. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ. 2004;328:1591-11527 (Pubitemid 38850305)
17. Petersen S, Peto V. Smoking Statistics. London, UK: British Heart Foundation; 2004.
18. Geiss LS, Herman WH, Smith PJ. Mortality in non-insulin dependent diabetes. In: Diabetes in America/National Diabetes Data Group, 2nd edn. Bethesda, MD: National Institutes of Health; 1995.
19. Garcia MJ, Mc Namara PM, Gordon T, Kannell WB. Morbidity and mortality in the Framingham population, sixteen years follow-up. Diabetes. 1974;23:105-111.
20. Hu FB, Stampfer MJ, Solomon CG, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow up. Arch Intern Med. 2001;161:1717.
21. Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischaemic heart disease, stroke and death: a population based study on 13 000 men and women with 20 years follow-up. Arch Intern Med. 2004; 164:1422.
22. Yarnell JW, Patterson CC, Thomas HF, et al. Central obesity: predictive value of skinfold measurements for subsequent ischaemic heart disease at 14 years follow-up in the Caerphilly Study. J Obes Relat Metab Disord. 2001;25: 1546-1549.
23. Manson JE, Willet WC, Stampfer MJ, et al. Body weight and mortality among women. N Engl J Med. 1995;333:677.
24. Blair SN, Kohl HW, Paffenbarger RS, et al. Physical fitness and all cause mortality: a prospective study of healthy men and women. JAMA. 1989;262:2395.
25. Bush TL, Fried LP, Barrett-Connor E. Cholesterol, lipoproteins and coronary heart disease in women. Clin Chem. 1988;34:B60-B70.
26. Manson JE, Hu FB, Rich-Edwards JW, et al. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med. 1999;341:650.
27. Kurisu S, Sato H, Kawagoe T, et al. Tako-tsubo like left ventricular dysfunction with ST-segment elevation: a novel cardiac syndrome mimicking acute myocardial infarction. Am Heart J. 2002;143:448-455. (Pubitemid 34185175)
28. Orth-Gomér K, Wamala SP, Horsten M, et al. Marital stress worsens prognosis in women with coronary heart disease: the Stockholm Female Coronary Risk Study. JAMA. 2000;284:3008-3014. (Pubitemid 32014737)
29. Rosengren A, Hawken S, Ounpuu S, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:953-962. (Pubitemid 39208456)
30. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-1712. (Pubitemid 38489892)